Teva Q1 2024: A Generics Engine Keeps Its 2024 Revenue Forecast On Track

Executive snapshot

Teva reported Q1 2024 revenue of $3.8 billion, up 5% in local currency versus the year-ago quarter. The company turned in a GAAP loss per share of $0.12, while non-GAAP diluted earnings per share (EPS) stood at $0.48. Operating cash flow was negative $124 million, with free cash flow at $32 million. The topline strength came alongside a mix shift: generics growth rose 9% globally in local currency terms, and key specialty products posted meaningful momentum.

For the year, Teva reaffirmed its revenue forecast of $15.7–$16.3 billion and an adjusted EBITDA range of $4.5–$5.0 billion. The quarter also showcased notable product and pipeline activity that could influence longer-term earnings trajectories.

Generics and specialty highlights

Generics continue to be the backbone, delivering robust growth across regions. The push in the U.S. included AUSTEDO growth of 67% year over year, signaling continued consumer and prescriber uptake within the specialty portfolio. In parallel, the company highlighted AJOVY revenues of $113 million for Q1 2024, up 18% from Q1 2023, underscoring steady demand in its branded neurology franchise.

Portfolio progress: approvals and pipeline

Teva noted recent FDA approvals of SIMLANDI and SELARSDI, biosimilars to Humira and Stelara, respectively—an explicit signal of the company’s ongoing push into biosimilars as a complement to its generics base. Management also announced positive Phase 3 efficacy results for olanzapine LAI (TEV’749) with no post-injection delirium/sedation syndrome (PDSS) observed to date, a development that could widen neurology/psychiatry exposure if later-stage data hold.

Earnings structure and outlook

On the earnings line, the reported numbers reflect a classic Teva narrative: GAAP losses versus non-GAAP profitability. Specifically, GAAP loss per share of $0.12 contrasts with a non-GAAP diluted EPS of $0.48. The distinction between GAAP and non-GAAP is a recurring theme in Teva’s reporting, shaping investor interpretation of cash generation and ongoing profitability.

Cash flow was modestly negative from operations at $124 million, with free cash flow of $32 million, illustrating the cash-cycle sensitivity that often accompanies a large, diversified portfolio—especially as the company funds pipeline investments and working-capital needs tied to the seasonality and timing of generic launches.

Outlook and what it implies for the quarter and peers

Teva reaffirmed its full-year 2024 revenue forecast of $15.7–$16.3 billion and an adjusted EBITDA bridge of $4.5–$5.0 billion. This reiteration, set against a Q1 that delivered a 5% local-currency top-line gain, suggests management is comfortable with the existing demand trajectory and cost structure even as it continues to lean into high-growth areas like AUSTEDO, AJOVY, and biosimilars. Analysts’ consensus expectations, often captured in an EPS consensus metric, were not disclosed in the release, so market interpretation will hinge on how investors weigh the mix shift toward specialty offerings versus the well-worn generics engine. In this sense, the quarter’s results align with a narrative of steady execution rather than a sudden earnings surprise.

The revenue forecast appears sensitive to product approvals, biosimilar uptake, and the pace of launches in the U.S. and international markets. The trajectory of AUSTEDO, AJOVY, and the readiness of SIMLANDI/SELARSDI to scale could substantially influence Teva’s EBITDA mix and free cash flow in 2024 and beyond. The absence of a dramatic swing in cash generation also keeps debt and working-capital considerations in focus for investors evaluating liquidity and capital allocation flexibility.

Implications for peers and the sector

Teva’s quarterly rhythm—combining a resilient generics backbone with selective high-growth brands and an expanding pipeline—offers a template for peers navigating the balance between volume-led revenue and the potential upside from specialty assets. The FDA approvals of SIMLANDI and SELARSDI highlight continued appetite for biosimilars as traditional drug pricing pressure persists. If TEV A’s pipeline milestones translate into durable revenue streams, sector peers may recalibrate expectations around biosimilar adoption, pricing environments, and the cadence of Phase 3 successes in schizophrenia/psychiatry and beyond.

Takeaways

• TEVA remains a generator of near-term revenue with a strong generics portfolio, augmented by growing specialty revenues (AUSTEDO, AJOVY).
• The company’s cash-flow picture shows modest operating cash flow in the quarter, with free cash flow still positive for the period, reinforcing a cautious but constructive view on capital allocation.
• Outlook reaffirmation underscores management’s confidence in the 2024 trajectory, even as investors watch for EPS catalysts from pipeline developments and biosimilar uptake.
• Pipeline progress and FDA approvals could shape the next leg of growth and influence how peers price risk around new launches and regulatory milestones.